Relay Therapeutics reported a Phase 2 efficacy signal for its isoform-selective PI3Kα inhibitor zovegalisib (RLY-2608) in patients with PIK3CA-driven vascular anomalies. The company said the trial met a key efficacy bar with a 60% volumetric response, surpassing expectations. Analyst commentary accompanying the readout estimates the second indication’s commercial upside, positioning vascular anomalies as a potential expansion beyond Relay’s broader oncology-focused development. The data arrive as PI3Kα inhibition remains one of the more actively pursued precision approaches for PIK3CA-related disease biology.